H ealth disparities are evident in Canada when comparing Aboriginal communities to the majority population, as Wassimi and colleagues point out in their study of perinatal and postneonatal mortality by birthweight. 1 In a step toward understanding the higher infant mortality among First Nations communities, the authors tackled the interesting question of whether there are survival advantages to large-for-gestational-age birthweight. In other words, are big babies better survivors? The study focused on First Nations people living in Quebec. Only those who reported speaking their First Nations language were included because they were identified in this manner. This population was compared with infants of Quebecers whose mother tongue is French.
The Cree of northern Quebec have very large infants owing to high pregravid body weights and high incidence of gestational diabetes. 2 The birthweight curve is shifted to the right compared with that for non-First Nations women. Whether this is a recent phenomenon is not clear. More importantly, the consequences for infant health in the first year of life are not well documented. In their follow-up analysis linking data on births and deaths up to one year of age, Wassimi and colleagues report very large differences in birthweight distribution between groups. Small-for-gestational-age births made up 4% in the First Nations group and 11% in the French-language group, and large-for-gestational-age births made up 28% in the First Nations group and 8% in the French-language group.
On close examination of the relative death rates in the two populations, one sees that, among appropriate-for-gestational-age infants, the relative risks of mortality are much higher in the First Nations group for both perinatal death (RR 1.77) and postneonatal death (RR 4.28). The First Nations group is clearly disadvantaged, with higher death rates in the small-for-gestational-age group as well.
Interestingly, however, there is no such disadvantage when perinatal mortality of large-forgestational-age infants is compared between the First Nations group and French-language control group. With only seven deaths in 10 years in the First Nations group, the effect is nonsignificant, and there is certainly no excess mortality. In fact, the lowest perinatal mortality within the First Nations group appears to be in the heaviest group. In contrast, large-for-gestational-age birthweight is a clear risk factor for perinatal mortality among infants of mothers whose mother tongue is French.
The findings for postneonatal mortality are complex and particularly intriguing. In the French-language group, there is a clear protective effect of large-for-gestational-age birthweight against postneonatal mortality, and this effect is even more evident when analysis is restricted to deaths caused by sudden infant death syndrome (SIDS). This advantage of large-for-gestational-age birthweight in regard to SIDS has also been observed in the United States, as reported by a US study linking infant birth and death certificates. 3 Among the First Nations infants, no such risk reduction for postneonatal mortality was seen. When one compares the First Nations outcomes by birthweight (within their own group), there is a very modest increase in postneonatal mortality and SIDS in the large-for-gestational-age group.
These two trends going in opposite directions would lead us to believe that First Nations infants who are born large for gestational age have a serious risk of postneonatal death. Certainly, First Nations infants are at higher risk of postneonatal mortality, but being heavy does not greatly exacerbate their high rates as one might conclude when comparing them to the large-for-
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gestational-age infants in the French-language group who are at reduced risk. How do we wish to make comparisons? First Nations groups might be interested in comparing mortality by birthweight within their own communities, and one would then have to argue that largefor-gestational-age babies are at minimal extra risk. By contrast, among mothers whose mother tongue is French, large-for-gestational-age birthweight confers a risk for perinatal death but is protective for postneonatal mortality and specifically SIDS. There is no doubt that First Nations infants are at higher risk for infant death, but the mortality patterns vary by differences in birthweight across populations in ways that we do not yet understand.
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